Biphasic mixtures of GLP-1 and insulin

• US 7,179,788 B2
• Filed: 10/07/2002
• Issued: 02/20/2007
• Est. Priority Date: 10/19/2001
• Status: Expired due to Fees

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: Ng, Kingman, DiMarchi, Richard Dennis, Trautmann, Michael Ernst, DeFelippis, Michael Rosario
• Primary Examiner(s): Gupta; Anish
• Application Number:
  US10/490,575
• Publication Number:
  US 20040254107A1
• Time in Patent Office: 1,597 Days
• Field of Search: None
• US Class Current: 514/6.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention encompasses pharmaceutical formulations comprising a biphasic mixture which comprises a glucagon like peptide (GLP-1) compound in a solid phase and an insulin in a solution phase.

Claims

1. A pharmaceutical formulation comprising a biphasic mixture which comprises a GLP-1 compound in a solid phase and an insulin in a solution phase.

2. The pharmaceutical formulation of claim 1 wherein the GLP-1 compound has a sequence selected from the group consisting of SEQ ID NO:

1, SEQ ID NO;

2, SEQ ID NO;

3, SEQ ID NO;

4, SEQ ID NO;

5, and SEQ ID NO;

6.

3. The pharmaceutical formulation of claim 1 wherein the insulin is selected from the group consisting of;

AspB28, AspB28-ProB29, LysB28, LysB28-ProB29, LysB3-GluB29, LeuB28, LeuB28-ProB29, ValB28, ValB28-ProB29, AlaB28, AlaB28-ProB29, des(B28-B30)-human insulin; and

des (B27)-human insulin.

4. The pharmaceutical formulation of claim 3 wherein the insulin is AspB28.

5. The pharmaceutical formulation of claim 3 wherein the insulin is LysB28-ProB29.

6. The pharmaceutical formulation of claim 1 wherein the GLP-1 compound has a sequence of SEQ ID NO:

2 or SEQ ID NO;

3 and the insulin is AspB28, LysB28-ProB29, or LysB3-GluB29.